CoChat
Sign Up
Cited by 128Sleep and related disordersDementia and Cognitive Impairment ResearchPharmaceutical Practices and Patient Outcomes

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pharmacotherapies for sleep disturbances in dementia

McCleery, Jenny, Sharpley, Ann L·2020·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd009178.pub4
Open this paper in CoChat — free account

Abstract

Background Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant carer distress, increased healthcare costs, and institutionalisation. Although non-drug interventions are recommended as the first-line approach to managing these problems, drug treatment is often sought and used. However, there is significant uncertainty about the efficacy and adverse effects of the various hypnotic drugs in this clinically vulnerable population. Objectives To assess the effects, including common adverse effects, of any drug treatment versus placebo for sleep disorders in people with dementia. Search methods We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, on 19 February 2020, using the terms: sleep, insomnia, circadian, hypersomnia, parasomnia, somnolence, rest-activity, and sundowning. Selection criteria We included randomised controlled trials (RCTs) that compared a drug with placebo, and that had the primary aim of improving sleep in people with dementia who had an identified sleep disturbance at baseline. Data collection and analysis Two review authors independently extracted data on study design, risk of bias, and results. We used the mean difference (MD) or risk ratio (RR) with 95% confidence intervals (CI) as the measures of treatment effect, and where possible, s…

Overview

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009178.pub4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Psychotic symptoms in dementia are associated with a particular tauopathy and neocortical synaptic disruption.

    “Psychotic symptoms in dementia are associated with a particular tauopathy and neocortical synaptic disruption but it is not known if these are causal.(535)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [535]

  • One review of nine RCTs rated low quality found low-certainty evidence in a small trial (n=30) that trazodone 50 mg for two weeks may improve time asleep but has no clear effect on other sleep parameters (MD 42.5 minutes, 0.9-84.0).

    “One review of nine RCTs rated to be lowquality (530) found low-certainty evidence in a small trial (n=30) that trazadone 50 mg for two weeks may improve time asleep but no clear effect on other sleep parameters (MD 42.5 minutes, 0.9 -84.0).”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [530]

  • Psychosis can precede dementia.

    “Psychosis can precede dementia and as discussed in the risk section; very late onset schizophrenia may be a dementia prodrome. (535)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [535]

  • Very late onset schizophrenia may be a dementia prodrome.

    “Psychosis can precede dementia and as discussed in the risk section; very late onset schizophrenia may be a dementia prodrome. (535)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [535]

  • There is less risk of stroke with risperidone for delusions than other indications.

    “Metaanalyses find risperidone and aripiprazole are the antipsychotics with the best evidence, with evidence that there is less risk of stroke with risperidone for delusions than other indications. (535) (2)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [535]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 83

  1. Camargos, 2014, Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind and placebo-controlled study, American Journal of Geriatric Psychiatry, 22, 1565, 10.1016/j.jagp.2013.12.174 · DOI · Paper page
  2. Camargos, 2015, Trazodone and cognitive performance in Alzheimer disease, Journal of Clinical Psychopharmacology, 35, 88, 10.1097/JCP.0000000000000237 · DOI · Paper page
  3. Dowling, 2008, Melatonin and bright light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease, American Journal of Geriatric Psychiatry, 56, 239, 10.1111/j.1532-5415.2007.01543.x · DOI
  4. Herring, 2018, Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer's disease: trial design and baseline characteristics of participants, Journal of Prevention of Alzheimer's Disease, 5, S195
  5. Herring, 2020, Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial, Alzheimer's & Dementia, 16, 541, 10.1002/alz.12035 · DOI · Paper page
  6. Morales-Delgado, 2018, A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia, European Geriatric Medicine, 9, 449, 10.1007/s41999-018-0068-9 · DOI
  7. Thein, 2019, Response to treatment with lemborexant: subjects with irregular sleep-wake rhythm disorder and Alzheimer's disease dementia, Alzheimer's & Dementia, 15 (7 Suppl), 187, 10.1016/j.jalz.2019.06.4392 · DOI
  8. Serfaty, 2002, Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia, International Journal of Geriatric Psychiatry, 17, 1120, 10.1002/gps.760 · DOI
  9. Singer, 2003, A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease, Sleep, 26, 893, 10.1093/sleep/26.7.893 · DOI · Paper page
  10. Wade, 2014, Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial, Clinical Interventions in Aging, 9, 947
  11. Asano, 2013, Effects of ramelteon on refractory behavioral and psychological symptoms of Alzheimer's disease, Journal of Clinical Psychopharmacology, 33, 579, 10.1097/JCP.0b013e3182946702 · DOI
  12. Asayama, 2003, Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia, Journal of Nippon Medical School, 70, 334, 10.1272/jnms.70.334 · DOI
  13. Bergener, 1968, Methods and problems of clinical psychopharmacology. Results of a double blind study with Medazepam and placebo in geriatric psychiatry, Arzneimittel-Forschung, 18, 1563
  14. Bergonzi, 1973, Tryptophan and sleep in subjects with neuropsychiatric syndromes, Rivista di Neurologia, 43, 403
  15. Blytt, 2018, Effects of pain treatment on sleep in nursing home patients with dementia and depression: a multicenter placebo-controlled randomized clinical trial, International Journal of Geriatric Psychiatry, 33, 663, 10.1002/gps.4839 · DOI
  16. Blytt, 2018, Long-term pain treatment did not improve sleep in nursing home patients with comorbid dementia and depression: a 13-week randomized placebo-controlled trial, Frontiers in Psychology, 9, 134, 10.3389/fpsyg.2018.00134 · DOI
  17. Cardinali, 2014, Melatonin therapy in patients with Alzheimer's disease, Antioxidants, 2, 245, 10.3390/antiox3020245 · DOI
  18. Cohen-Mansfield, 2000, Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study, Archives of Gerontology and Geriatrics, 31, 65, 10.1016/S0167-4943(00)00068-6 · DOI
  19. Cruz-Aguilar, 2013, Melatonin effects on macro sleep architecture in Alzheimer's disease patients, Salud Mental, 36, 243
  20. Gehrmann, 2009, Melatonin fails to improve sleep or agitation in a double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer's disease, American Journal of Geriatric Psychiatry, 17, 166, 10.1097/JGP.0b013e318187de18 · DOI
  21. Gillman, 1997, Tacrine for treatment of sleep disturbance in dementia, Journal of the American Geriatrics Society, 45, 1286, 10.1111/j.1532-5415.1997.tb03794.x · DOI
  22. Ginsburg, 1976, Caffeine in the 'Sundown syndrome'. Report of negative results, Journal of Gerontology, 31, 419, 10.1093/geronj/31.4.419 · DOI
  23. Hamuro, 2018, Suvorexant for the treatment of insomnia in patients with Alzheimer's disease, Australian & New Zealand Journal of Psychiatry, 52, 207, 10.1177/0004867417747402 · DOI
  24. Howcroft, 2005, Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia?, International Journal of Geriatric Psychiatry, 20, 492, 10.1002/gps.1305 · DOI
  25. Kittur, 1999, Improvement of sleep and behavior by methylphenidate in Alzheimer's disease, American Journal of Psychiatry, 156, 1116, 10.1176/ajp.156.7.1116 · DOI
  26. Linnoila, 1980, Efficacy and side effects of chloral hydrate and tryptophan as sleeping aids in psychogeriatric patients, International Pharmacopsychiatry, 15, 124, 10.1159/000468423 · DOI
  27. Linnoila, 1980, Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric in-patients, International Pharmacopsychiatry, 15, 129, 10.1159/000468424 · DOI
  28. Magnus, 1978, A controlled trial of chlormethiazole in the management of symptoms of the organic dementias in the elderly, Clinical Therapeutics, 1, 387
  29. Mahlberg, 2004, Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease:‭ ‬an open-label pilot study using actigraphy, Journal of Clinical Psychopharmacology, 24, 456, 10.1097/01.jcp.0000132443.12607.fd · DOI
  30. Markowitz, 2003, Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine, Sleep, 26, 602, 10.1093/sleep/26.5.602 · DOI
  31. Meguro, 2004, Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease, Journal of Geriatric Psychiatry and Neurology, 17, 61, 10.1177/0891988704264535 · DOI
  32. Mishima, 1992, Effect of methylcobalamin (VB12) injection on sleep-wake rhythm in demented patients, Japanese Journal of Psychiatry & Neurology, 46, 227
  33. Moraes, 2003, Six-month donepezil treatment alters REM sleep parameters in Alzheimer's disease patients: a double-blind placebo controlled study, Sleep, 26, A351
  34. Moraes, 2006, The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study, Sleep, 29, 199, 10.1093/sleep/29.2.199 · DOI
  35. Petit, 1993, THA does not affect sleep or EEG spectral power in Alzheimer's disease, Biological Psychiatry, 33, 753, 10.1016/0006-3223(93)90128-Z · DOI
  36. Riley McCarten, 1995, Triazolam in Alzheimer's disease: pilot study on sleep and memory effects, Pharmacology, Biochemistry and Behavior, 52, 447, 10.1016/0091-3057(95)00116-E · DOI
  37. Ruths, 2004, Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study, Journal of the American Geriatrics Society, 52, 1737, 10.1111/j.1532-5415.2004.52470.x · DOI
  38. Schubert, 1984, Hydroxyzine for acute treatment of agitation and insomnia in organic mental disorder, Psychiatric Journal of the University of Ottawa, 9, 59
  39. Scoralick, 2017, Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study, Psychogeriatrics, 17, 89, 10.1111/psyg.12191 · DOI · Paper page
  40. Scripnikov, 2007, Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial, Wiener Medizinische Wochenschrift, 157, 295, 10.1007/s10354-007-0427-5 · DOI
  41. Shaw, 1992, A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients, Journal of International Medical Research, 20, 150, 10.1177/030006059202000207 · DOI
  42. Shinno, 2008, Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia, Progress in Neuro-Psychopharmacology‭ & ‬Biological Psychiatry, 32, 881, 10.1016/j.pnpbp.2007.12.027 · DOI
  43. Simon Padilla, 2009, Use of combined treatment with melatonin and clomethiazole in circadian rhythm sleep disorder in the elderly with dementia, Revista Espanola de Geriatria y Gerontologia, 44, 233
  44. Singer, 2007, Modafinil vs. placebo: effects on daytime sleep in Alzheimer's disease, Biological Psychiatry, 61, 144S
  45. Stahl, 2004, Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease, Current Medical Research and Opinion, 20, 517, 10.1185/030079904125003214 · DOI
  46. Stemmelin, 2013, A phase 2 study to investigate the effects of Sar110894 on cognition, daily function, apathy and sleep in mild to moderate Alzheimer's disease patients, Journal of Nutrition, Health and Aging, 804
  47. Valtonen, 2005, Effects of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects, Nordic Journal of Psychiatry, 59, 217, 10.1080/08039480510023034 · DOI
  48. Walther, 2011, Randomized, controlled, crossover trial of dronabinol, 2.5mg, for agitation in 2 patients with dementia, Journal of Clinical Psychopharmacology, 31, 254, 10.1097/JCP.0b013e31820e861c · DOI
  49. Yehuda, 1996, Essential fatty acids preparation (sr-3) improves Alzheimer's patients quality of life, International Journal of Neuroscience, 87, 141, 10.3109/00207459609070833 · DOI
  50. Afram, 2014, Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries, JAMDA, 15, 108, 10.1016/j.jamda.2013.09.012 · DOI · Paper page
  51. Ancoli-Israel, 1997, Use of wrist actigraphy for monitoring sleep/wake in demented nursing home patients, Sleep, 20, 24, 10.1093/sleep/20.1.24 · DOI
  52. Bliwise, 2011, Sleep disturbance in dementia with Lewy bodies and Alzheimer's disease: a multicenter analysis, Dementia & Geriatric Cognitive Disorders, 31, 239, 10.1159/000326238 · DOI
  53. Borbély, 2016, The two-process model of sleep regulation: a reappraisal, Journal of Sleep Research, 25, 131, 10.1111/jsr.12371 · DOI · Paper page
  54. Buxton, 2000, A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag, Sleep, 23, 915, 10.1093/sleep/23.7.1g · DOI
  55. Camargos, 2013, Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness and challenges, Sleep Medicine Reviews, 17, 475, 10.1016/j.smrv.2013.01.006 · DOI
  56. Cardinali, 2010, Clinical aspects of melatonin intervention in Alzheimer's disease progression, Current Neuropharmacology, 8, 218, 10.2174/157015910792246209 · DOI
  57. Closser, 1991, Benzodiazepines and the elderly: a review of potential problems, Journal of Substance Abuse Treatment, 8, 35, 10.1016/0740-5472(91)90025-6 · DOI
  58. Coupland, 2011, A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database, Health Technology Assessment, 15, 1, 10.3310/hta15280 · DOI
  59. Cumming, 2003, Benzodiazepines and risk of hip fractures in older people: a review of the evidence, CNS Drugs, 17, 825, 10.2165/00023210-200317110-00004 · DOI
  60. Donaldson, 1998, Determinants of carer stress in Alzheimer's disease, International Journal of Geriatric Psychiatry, 13, 248, 10.1002/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0 · DOI · Paper page
  61. Cummings, 2005, Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia, Journal of Neurology, Neurosurgery and Psychiatry, 76, 1337, 10.1136/jnnp.2004.056408 · DOI
  62. Gao, 2009, Effect of melatonin on mild Alzheimer's disease in elderly male patients, Practical Geriatrics, 23, 56
  63. Gaugler, 2000, Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement, Journals of Gerontology. Series B, Psychological Sciences and Social Sciences, 55, 247, 10.1093/geronb/55.4.P247 · DOI
  64. Gehrman, 2018, Impact of Alzheimer disease patients' sleep disturbances on their caregivers, Geriatric Nursing, 39, 60, 10.1016/j.gerinurse.2017.06.003 · DOI
  65. Goodman, 2017, Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013, Alzheimer's & Dementia, 13, 28, 10.1016/j.jalz.2016.04.002 · DOI
  66. Guarnieri, 2012, Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian cross-sectional study on 431 patients, Dementia & Geriatric Cognitive Disorders, 33, 50, 10.1159/000335363 · DOI · Paper page
  67. Hart, 2003, A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease, International Journal of Geriatric Psychiatry, 18, 1037, 10.1002/gps.1013 · DOI
  68. Herring, 2017, Suvorexant in elderly patients with insomnia: pooled analyses of data from Phase III randomized controlled clinical trials, American Journal of Psychiatry, 25, 791, 10.1016/j.jagp.2017.03.004 · DOI
  69. Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
  70. Howard, 2011, Determining the minimum clinically important differences for outcomes in the DOMINO trial, International Journal of Geriatric Psychiatry, 26, 812, 10.1002/gps.2607 · DOI · Paper page
  71. Li, 2019, Interaction between the progression of Alzheimer's dementia and circadian disturbances: a 13-year longitudinal study in community-based older adults, Sleep, 42, A123, 10.1093/sleep/zsz067.300 · DOI
  72. Liguori, 2014, Orexineric system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease, JAMA Neurology, 71, 1498, 10.1001/jamaneurol.2014.2510 · DOI
  73. Lyketsos, 2000, Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging, American Journal of Psychiatry, 157, 708, 10.1176/appi.ajp.157.5.708 · DOI · Paper page
  74. Mishima, 2000, Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons, Chronobiology International, 17, 419, 10.1081/CBI-100101055 · DOI
  75. Papillon-Ferland, 2019, Should melatonin be used as a sleeping aid for elderly people?, Canadian Journal of Hospital Pharmacy, 72, 327
  76. Rongve, 2010, Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia, Journal of the American Geriatrics Society, 58, 480, 10.1111/j.1532-5415.2010.02733.x · DOI
  77. Schneider, 2005, Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials, JAMA, 294, 1934, 10.1001/jama.294.15.1934 · DOI · Paper page
  78. Schneider, 2006, Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials, American Journal of Geriatric Psychiatry, 14, 191, 10.1097/01.JGP.0000200589.01396.6d. · DOI · Paper page
  79. Van Egroo, 2019, Sleep-wake regulation and the hallmarks of the pathogenesis of Alzheimer's disease, Sleep, 42, zsz017, 10.1093/sleep/zsz017 · DOI
  80. Wilfling, 2015, Non-pharmacological interventions for sleep disturbances in people with dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011881 · DOI
  81. Xu, 2015, Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials, American Journal of Alzheimer's Disease and Other Dementias, 30, 439, 10.1177/1533317514568005 · DOI
  82. McCleery, 2014, Pharmacotherapies for sleep disturbances in Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009178.pub2 · DOI
  83. McCleery, 2016, Pharmacotherapies for sleep disturbances in dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009178.pub3 · DOI

Cited by

Sorted by citations

Metadata

Authors
McCleery, J., & Sharpley, A. L.
Affiliations
  • Oxford Health NHS Foundation Trust (GB)
  • University of Oxford (GB)
ORCID
Sharpley, Ann L
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2020-11-15
Volume
2020
Issue
11
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd009178.pub4
OpenAlex
W4211193256
Cited by
128
References
3
Citations by year
2026: 15 · 2025: 31 · 2024: 25 · 2023: 19 · 2022: 23 · 2021: 14 · 2020: 1
FWCI
2.08
Type
journal article
Language
en
Open access
closed
Locations
Cochrane Database of Systematic Reviews (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
sleep disorders, dementia, pharmacotherapy, hypnotics, nocturnal wandering, daytime sleepiness, sleep fragmentation, caregiver distress, adverse drug reactions, institutionalization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review